In an evaluation of 49 top-selling brand-name drugs, 28 of the drugs available since 2012 saw an increase in insurer and out-of-pocket costs of more than 50 percent by 2017 and 16 more than doubled in price, according to a study reported Friday in JAMA Network Open. The study examined pharmacy claims data for more than 35 million people with private pharmaceutical insurance. 
 

Related News Articles

Headline
Health and Human Services Secretary Alex Azar today released a plan outlining two pathways the administration intends to explore to safely import certain drugs…
Headline
The Senate Finance Committee today voted 19-9 to pass the Prescription Drug Pricing Reduction Act, legislation to reduce drug costs.
Headline
Senate Finance Committee Chairman Chuck Grassley, R-Iowa, and Ranking Member Ron Wyden, D-Ore., today released a description of the chairman’s mark, the…
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The Trump administration today withdrew a proposed rule that would eliminate the rebate safe harbor for pharmacy benefit managers under the federal anti-…
Headline
A federal judge yesterday struck down a Centers for Medicare…